Compare · OM vs TMDX
OM vs TMDX
Side-by-side comparison of Outset Medical Inc. (OM) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both OM and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $2.41B, about 28.2x OM ($85.3M).
- OM has been more active in the news (14 items in the past 4 weeks vs 12 for TMDX).
- TMDX has more recent analyst coverage (18 ratings vs 13 for OM).
- Company
- Outset Medical Inc.
- TransMedics Group Inc.
- Price
- -
- -
- Market cap
- $85.3M
- $2.41B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2019
- News (4w)
- 14
- 12
- Recent ratings
- 13
- 18
Outset Medical Inc.
Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It offers Tablo Hemodialysis System, which comprises of a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest OM
- Outset Medical Inc. filed SEC Form 8-K: Leadership Update
- SEC Form SD filed by Outset Medical Inc.
- Outset Medical Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Chair and CEO Trigg Leslie sold $12,746 worth of shares (3,445 units at $3.70), decreasing direct ownership by 3% to 98,874 units (SEC Form 4) to satisfy tax liability
- EVP Operations R&D & Service Nash Marc sold $5,853 worth of shares (1,582 units at $3.70), decreasing direct ownership by 4% to 38,393 units (SEC Form 4) (tax withholding)
- General Counsel Brottem John L. sold $9,761 worth of shares (2,638 units at $3.70), decreasing direct ownership by 8% to 30,277 units (SEC Form 4) (for withholding tax)
- Amendment: SEC Form SCHEDULE 13G/A filed by Outset Medical Inc.
- Large owner Leonard Braden Michael exercised 323,000 in-the-money shares at a strike of $5.00 (SEC Form 4)
- SEC Form 144 filed by Outset Medical Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Outset Medical Inc.
Latest TMDX
- SEC Form SD filed by TransMedics Group Inc.
- Director Basile Edward M was granted 2,922 shares, increasing direct ownership by 102% to 5,788 units (SEC Form 4)
- Director Gunderson Thomas J. was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)
- Director Raines Merilee was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)
- Director Weill David was granted 2,922 shares, increasing direct ownership by 24% to 15,056 units (SEC Form 4)
- Director Lovell Stephanie was granted 2,922 shares, increasing direct ownership by 102% to 5,788 units (SEC Form 4)
- Director Tobin James R was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)
- Director Kania Edwin was granted 2,922 shares, increasing direct ownership by 1% to 263,732 units (SEC Form 4)
- Officer Forsyth Matthew S. was granted 15,409 shares (SEC Form 4)
- SEC Form 8-K filed by TransMedics Group Inc.